不同回溯期构建倾向评分对匹配估计的影响:哮喘儿童药物有效性回顾性队列研究
该研究基于荷兰初级保健数据库构建5-17岁哮喘儿童队列,比较固定与松散ICS+LABA组合预防重度哮喘急性发作的效果。使用1周至全病史5种回溯期构建倾向评分并匹配,粗HR为0.37,匹配后HR为0.48至0.69且置信区间均含1。结论认为不同回溯期影响估计,3个月回溯期可能获得与临床试验可比的结果。
要点
- 在39,682名哮喘儿童中,3,500名(8.8%)为新使用ICS+LABA者。
- 固定组合与松散组合比较,粗HR为0.37(95%CI 0.20-0.66)。
- 不同回溯期PS匹配后HR为0.48至0.69,95%CI均包含1。
核心结论
- PS匹配可用于控制儿科比较药物有效性研究中的混杂,不同回溯期实施PS的影响重要。
- 控制药物暴露前3个月发生的混杂因素可能获得与临床试验结果可比的结果。
研究设计与样本
- 基于荷兰Integrated Primary Care information数据库的回顾性队列研究。
- 纳入5-17岁诊断为哮喘的儿童,识别新使用ICS+LABA固定组合或松散组合者。
- 使用1周、1月、3月、1年和全病史5种回溯期构建倾向评分并匹配。
- 采用Cox比例风险回归分析至首次哮喘急性发作时间,并与已发表临床试验比较。
主要发现
- 39,682名哮喘儿童中,3,500名(8.8%)为新使用ICS+LABA者;固定组合3,324名(95.0%),松散组合176名(5.0%)。
- 固定组合与松散组合比较,重度哮喘急性发作的粗HR为0.37(95%CI 0.20-0.66)。
- PS匹配后HR:1周回溯期0.48(95%CI 0.22-1.04);1月0.60(95%CI 0.26-1.38);3月0.69(95%CI 0.31-1.57);1年0.56(95%CI 0.25-1.24);全病史0.58(95%CI 0.24-1.36)。
关键数值与推荐
- PS匹配后各回溯期HR的95%CI均包含1。
临床怎么用
- 在儿科比较药物有效性研究中,使用PS匹配控制适应证混杂时,回溯期的选择影响估计值。
- 控制药物暴露前3个月发生的混杂因素,可能获得与临床试验结果可比的结果。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To control for confounding by indication in comparative (drug) effectiveness studies, propensity score (PS) methods may be used. Since childhood diseases or outcomes often present as acute events, we compared the effect of using different look-back periods in electronic health-care data, to construct PSs. This was applied in our research on the effect of a combination of inhaled corticosteroids/long-acting beta-2 agonists (ICS + LABA), either as fixed combination or used as loose combination (2 separate inhaler devices) in the prevention of severe asthma exacerbations. METHODS: We created a cohort of children (5-17 years) diagnosed with asthma from the Dutch Integrated Primary Care information database. Within this cohort, we identified new users of ICS + LABA, either as fixed combination or loose combination (2 separate inhaler devices). The outcome of interest was severe asthma exacerbations. PSs for type of treatment were created using comorbidity and drug use history in different time windows: 1 week, 1 month, 3 months, 1 year, and full history prior to the start of treatment. PSs were used for matching subjects in both exposure groups. Time to first asthma exacerbation was analyzed with Cox proportional hazard regression. The results were compared with published clinical trials. RESULTS: Of 39,682 asthmatic children, 3,500 (8.8%) were new users of either ICS + LABA fixed (3,324 [95.0%]) or loose (176 [5.0%]). The crude hazard ratio (HR) for a severe asthma exacerbation, comparing ICS + LABA fixed to loose was 0.37 (95% confidence interval [CI]: 0.20-0.66). PS-matched HRs (1 week, 1 month, 3 month, 1 year, and full history) were 0.48 (95% CI: 0.22-1.04); 0.60 (95% CI: 0.26-1.38), 0.69 (95% CI: 0.31-1.57), 0.56 (CI: 0.25-1.24), and 0.58 (CI: 0.24-1.36), respectively. CONCLUSIONS: PS matching can be used to control for confounding in pediatric comparative (drug) effectiveness studies, the impact of different look-back periods to implement the PS is important. Controlling for confounders occurring in the 3 months preceding drug exposure may yield results comparable to clinical trial results.
引用
- Osokogu OU, Khan J, Nakato S, et al. Choice of time period to identify confounders for propensity score matching, affected the estimate: a retrospective cohort study of drug effectiveness in asthmatic children. J Clin Epidemiol. 2018. PMID: 29378305. doi:10.1016/j.jclinepi.2018.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。